OMERS ADMINISTRATION Corp Acquires New Stake in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX)

OMERS ADMINISTRATION Corp acquired a new position in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX - Free Report) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm acquired 66,000 shares of the company's stock, valued at approximately $249,000. OMERS ADMINISTRATION Corp owned approximately 0.10% of Amylyx Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also bought and sold shares of the business. Boxer Capital Management LLC purchased a new position in Amylyx Pharmaceuticals during the fourth quarter valued at $6,615,000. Bank of America Corp DE boosted its holdings in shares of Amylyx Pharmaceuticals by 165.9% in the 4th quarter. Bank of America Corp DE now owns 2,426,263 shares of the company's stock valued at $9,171,000 after acquiring an additional 1,513,748 shares during the last quarter. Cubist Systematic Strategies LLC boosted its holdings in shares of Amylyx Pharmaceuticals by 862.5% in the 4th quarter. Cubist Systematic Strategies LLC now owns 472,397 shares of the company's stock valued at $1,786,000 after acquiring an additional 423,316 shares during the last quarter. Jane Street Group LLC boosted its holdings in shares of Amylyx Pharmaceuticals by 122.4% in the 4th quarter. Jane Street Group LLC now owns 765,475 shares of the company's stock valued at $2,893,000 after acquiring an additional 421,302 shares during the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. boosted its holdings in shares of Amylyx Pharmaceuticals by 43.4% in the 4th quarter. Connor Clark & Lunn Investment Management Ltd. now owns 1,263,353 shares of the company's stock valued at $4,775,000 after acquiring an additional 382,608 shares during the last quarter. Hedge funds and other institutional investors own 95.84% of the company's stock.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on AMLX shares. Mizuho boosted their target price on shares of Amylyx Pharmaceuticals from $7.00 to $8.00 and gave the company an "outperform" rating in a research note on Wednesday, May 14th. Leerink Partners upgraded shares of Amylyx Pharmaceuticals from a "market perform" rating to an "outperform" rating and upped their price objective for the stock from $4.00 to $10.00 in a research report on Wednesday, May 7th. HC Wainwright upped their price objective on shares of Amylyx Pharmaceuticals from $12.00 to $16.00 and gave the stock a "buy" rating in a research report on Friday, May 9th. Finally, Leerink Partnrs upgraded shares of Amylyx Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a research report on Tuesday, May 6th. One equities research analyst has rated the stock with a hold rating, five have issued a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat.com, Amylyx Pharmaceuticals has a consensus rating of "Buy" and a consensus target price of $9.83.

Insider Activity at Amylyx Pharmaceuticals

In related news, Director Bernhardt G. Zeiher bought 10,000 shares of the stock in a transaction on Thursday, March 20th. The stock was bought at an average price of $3.70 per share, with a total value of $37,000.00. Following the completion of the purchase, the director now directly owns 10,000 shares in the company, valued at $37,000. This represents a ∞ increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Joshua B. Cohen sold 21,490 shares of the stock in a transaction dated Monday, March 31st. The stock was sold at an average price of $3.47, for a total transaction of $74,570.30. Following the transaction, the chief executive officer now directly owns 3,355,280 shares of the company's stock, valued at approximately $11,642,821.60. This trade represents a 0.64% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 48,980 shares of company stock valued at $168,627. 11.70% of the stock is owned by company insiders.

Amylyx Pharmaceuticals Price Performance

Shares of AMLX traded down $0.05 during mid-day trading on Friday, reaching $5.31. The stock had a trading volume of 906,493 shares, compared to its average volume of 1,221,238. Amylyx Pharmaceuticals, Inc. has a 52-week low of $1.58 and a 52-week high of $7.27. The business's fifty day moving average is $4.31 and its 200 day moving average is $4.17. The firm has a market cap of $473.34 million, a price-to-earnings ratio of -1.39 and a beta of -0.60.

Amylyx Pharmaceuticals (NASDAQ:AMLX - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The company reported ($0.42) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.45) by $0.03. As a group, sell-side analysts anticipate that Amylyx Pharmaceuticals, Inc. will post -2.2 EPS for the current fiscal year.

Amylyx Pharmaceuticals Company Profile

Amylyx Pharmaceuticals, Inc, a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada.